Literature DB >> 24789780

Mechanistic differences between nucleic acid chaperone activities of the Gag proteins of Rous sarcoma virus and human immunodeficiency virus type 1 are attributed to the MA domain.

Tiffiny D Rye-McCurdy1, Shorena Nadaraia-Hoke2, Nicole Gudleski-O'Regan3, John M Flanagan4, Leslie J Parent2, Karin Musier-Forsyth5.   

Abstract

Host cell tRNAs are recruited for use as primers to initiate reverse transcription in retroviruses. Human immunodeficiency virus type 1 (HIV-1) uses tRNA(Lys3) as the replication primer, whereas Rous sarcoma virus (RSV) uses tRNA(Trp). The nucleic acid (NA) chaperone function of the nucleocapsid (NC) domain of HIV-1 Gag is responsible for annealing tRNA(Lys3) to the genomic RNA (gRNA) primer binding site (PBS). Compared to HIV-1, little is known about the chaperone activity of RSV Gag. In this work, using purified RSV Gag containing an N-terminal His tag and a deletion of the majority of the protease domain (H6.Gag.3h), gel shift assays were used to monitor the annealing of tRNA(Trp) to a PBS-containing RSV RNA. Here, we show that similar to HIV-1 Gag lacking the p6 domain (GagΔp6), RSV H6.Gag.3h is a more efficient chaperone on a molar basis than NC; however, in contrast to the HIV-1 system, both RSV H6.Gag.3h and NC have comparable annealing rates at protein saturation. The NC domain of RSV H6.Gag.3h is required for annealing, whereas deletion of the matrix (MA) domain, which stimulates the rate of HIV-1 GagΔp6 annealing, has little effect on RSV H6.Gag.3h chaperone function. Competition assays confirmed that RSV MA binds inositol phosphates (IPs), but in contrast to HIV-1 GagΔp6, IPs do not stimulate RSV H6.Gag.3h chaperone activity unless the MA domain is replaced with HIV-1 MA. We conclude that differences in the MA domains are primarily responsible for mechanistic differences in RSV and HIV-1 Gag NA chaperone function. Importance: Mounting evidence suggests that the Gag polyprotein is responsible for annealing primer tRNAs to the PBS to initiate reverse transcription in retroviruses, but only HIV-1 Gag chaperone activity has been demonstrated in vitro. Understanding RSV Gag's NA chaperone function will allow us to determine whether there is a common mechanism among retroviruses. This report shows for the first time that full-length RSV Gag lacking the protease domain is a highly efficient NA chaperone in vitro, and NC is required for this activity. In contrast to results obtained for HIV-1 Gag, due to the weak nucleic acid binding affinity of the RSV MA domain, inositol phosphates do not regulate RSV Gag-facilitated tRNA annealing despite the fact that they bind to MA. These studies provide insight into the viral regulation of tRNA primer annealing, which is a potential target for antiretroviral therapy.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24789780      PMCID: PMC4097784          DOI: 10.1128/JVI.00736-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

1.  Nuclear entry and CRM1-dependent nuclear export of the Rous sarcoma virus Gag polyprotein.

Authors:  Lisa Z Scheifele; Rachel A Garbitt; Jonathan D Rhoads; Leslie J Parent
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

Review 2.  HIV-1 assembly, budding, and maturation.

Authors:  Wesley I Sundquist; Hans-Georg Kräusslich
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

3.  Special issue: Structural and molecular biology of HIV.

Authors:  Michael F Summers; Jonathan Karn
Journal:  J Mol Biol       Date:  2011-07-22       Impact factor: 5.469

4.  Structural genomics of enzymes involved in sterol/isoprenoid biosynthesis.

Authors:  J B Bonanno; C Edo; N Eswar; U Pieper; M J Romanowski; V Ilyin; S E Gerchman; H Kycia; F W Studier; A Sali; S K Burley
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

5.  Rous sarcoma virus Gag protein-oligonucleotide interaction suggests a critical role for protein dimer formation in assembly.

Authors:  Yu May Ma; Volker M Vogt
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  trans-acting inhibition of genomic RNA dimerization by Rous sarcoma virus matrix mutants.

Authors:  R A Garbitt; J A Albert; M D Kessler; L J Parent
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

7.  Repositioning basic residues in the M domain of the Rous sarcoma virus gag protein.

Authors:  E M Callahan; J W Wills
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 8.  tRNA(Lys3): the primer tRNA for reverse transcription in HIV-1.

Authors:  Lawrence Kleiman
Journal:  IUBMB Life       Date:  2002-02       Impact factor: 3.885

9.  Sequence-specific interaction between HIV-1 matrix protein and viral genomic RNA revealed by in vitro genetic selection.

Authors:  P Purohit; S Dupont; M Stevenson; M R Green
Journal:  RNA       Date:  2001-04       Impact factor: 4.942

10.  A novel fluorescence resonance energy transfer assay demonstrates that the human immunodeficiency virus type 1 Pr55Gag I domain mediates Gag-Gag interactions.

Authors:  Aaron Derdowski; Lingmei Ding; Paul Spearman
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more
  9 in total

1.  HIV-1 Pr55Gag binds genomic and spliced RNAs with different affinity and stoichiometry.

Authors:  Serena Bernacchi; Ekram W Abd El-Wahab; Noé Dubois; Marcel Hijnen; Redmond P Smyth; Johnson Mak; Roland Marquet; Jean-Christophe Paillart
Journal:  RNA Biol       Date:  2016-11-14       Impact factor: 4.652

2.  Solution Conformation of Bovine Leukemia Virus Gag Suggests an Elongated Structure.

Authors:  Dominic F Qualley; Sarah E Cooper; James L Ross; Erik D Olson; William A Cantara; Karin Musier-Forsyth
Journal:  J Mol Biol       Date:  2019-02-04       Impact factor: 5.469

Review 3.  Retroviral Gag protein-RNA interactions: Implications for specific genomic RNA packaging and virion assembly.

Authors:  Erik D Olson; Karin Musier-Forsyth
Journal:  Semin Cell Dev Biol       Date:  2018-04-01       Impact factor: 7.727

4.  Thermodynamic instability of viral proteins is a pathogen-associated molecular pattern targeted by human defensins.

Authors:  Elena Kudryashova; Pratibha C Koneru; Mamuka Kvaratskhelia; Adam A Strömstedt; Wuyuan Lu; Dmitri S Kudryashov
Journal:  Sci Rep       Date:  2016-09-01       Impact factor: 4.379

5.  The matrix domain contributes to the nucleic acid chaperone activity of HIV-2 Gag.

Authors:  Katarzyna Pachulska-Wieczorek; Leszek Błaszczyk; Marcin Biesiada; Ryszard W Adamiak; Katarzyna J Purzycka
Journal:  Retrovirology       Date:  2016-03-17       Impact factor: 4.602

6.  Rous Sarcoma Virus Genomic RNA Dimerization Capability In Vitro Is Not a Prerequisite for Viral Infectivity.

Authors:  Shuohui Liu; Rebecca Kaddis Maldonado; Tiffiny Rye-McCurdy; Christiana Binkley; Aissatou Bah; Eunice C Chen; Breanna L Rice; Leslie J Parent; Karin Musier-Forsyth
Journal:  Viruses       Date:  2020-05-22       Impact factor: 5.048

7.  Membrane binding and subcellular localization of retroviral Gag proteins are differentially regulated by MA interactions with phosphatidylinositol-(4,5)-bisphosphate and RNA.

Authors:  Jingga Inlora; David R Collins; Marc E Trubin; Ji Yeon J Chung; Akira Ono
Journal:  MBio       Date:  2014-12-09       Impact factor: 7.867

8.  Functional Equivalence of Retroviral MA Domains in Facilitating Psi RNA Binding Specificity by Gag.

Authors:  Tiffiny Rye-McCurdy; Erik D Olson; Shuohui Liu; Christiana Binkley; Joshua-Paolo Reyes; Brian R Thompson; John M Flanagan; Leslie J Parent; Karin Musier-Forsyth
Journal:  Viruses       Date:  2016-09-19       Impact factor: 5.048

9.  RNA-Binding Domains of Heterologous Viral Proteins Substituted for Basic Residues in the RSV Gag NC Domain Restore Specific Packaging of Genomic RNA.

Authors:  Breanna L Rice; Timothy L Lochmann; Leslie J Parent
Journal:  Viruses       Date:  2020-03-27       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.